← Back to Screener
Olema Pharmaceuticals, Inc. Common Stock (OLMA)
Price$10.31
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-71.52%
Price vs S&P 500 (4W)-30.80%
VGM Score34.28
Market Capitalization$900.55M
All Metrics
Book Value / Share (Quarterly)$5.50
P/TBV (Annual)3.88x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.70
Price vs S&P 500 (YTD)-66.92%
EPS (TTM)$-2.02
10-Day Avg Trading Volume1.50M
EPS Excl Extra (TTM)$-2.02
EPS (Annual)$-1.87
ROI (Annual)-33.73%
Cash / Share (Quarterly)$5.79
ROA (Last FY)-30.45%
EBITD / Share (TTM)$-2.20
ROE (5Y Avg)-36.34%
Cash Flow / Share (Annual)$-1.80
P/B Ratio1.87x
P/B Ratio (Quarterly)2.70x
Net Income / Employee (Annual)$-1,240,100
Net Interest Coverage (TTM)-36.49x
ROA (TTM)-41.18%
EPS Incl Extra (Annual)$-1.87
Current Ratio (Annual)9.95x
Quick Ratio (Quarterly)10.81x
3-Month Avg Trading Volume1.47M
52-Week Price Return144.89%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$5.04
52-Week High$36.26
EPS Excl Extra (Annual)$-1.87
26-Week Price Return-63.59%
Quick Ratio (Annual)9.85x
13-Week Price Return-54.30%
Total Debt / Equity (Annual)0.01x
Current Ratio (Quarterly)10.88x
Enterprise Value$851.01M
Book Value / Share Growth (5Y)-7.33%
Revenue / Employee (Annual)$0
Cash / Share (Annual)$6.21
3-Month Return Std Dev82.62%
Net Income / Employee (TTM)$-1,413,400
ROE (Last FY)-33.95%
EPS Basic Excl Extra (Annual)$-1.87
Total Debt / Equity (Quarterly)0.01x
EPS Incl Extra (TTM)$-2.02
ROI (TTM)-45.61%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$4.90
Price vs S&P 500 (52W)120.53%
Year-to-Date Return-58.76%
5-Day Price Return-18.88%
EPS Normalized (Annual)$-1.87
ROA (5Y Avg)-33.34%
Month-to-Date Return-21.83%
Cash Flow / Share (TTM)$-2.30
EBITD / Share (Annual)$-2.05
LT Debt / Equity (Annual)0.01x
ROI (5Y Avg)-36.30%
LT Debt / Equity (Quarterly)0.01x
EPS Basic Excl Extra (TTM)$-2.02
P/TBV (Quarterly)2.79x
P/B Ratio (Annual)4.11x
Book Value / Share (Annual)$5.88
Price vs S&P 500 (13W)-62.55%
Beta2.06x
Revenue / Share (TTM)$0.00
ROE (TTM)-45.95%
52-Week Low$3.89
mGradeD
vgmGradeD
Show chart for
Earnings Surprise History
Q1 26-0.52est. -0.54
Q1 26-0.52est. -0.54
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.29
4.33
4.26
4.26
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
OLMAOlema Pharmaceuticals, Inc. Common Stock | — | — | D | $10.31 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Olema Pharmaceuticals is a clinical-stage biopharmaceutical company focused on targeted therapies for women's cancers. Its pipeline includes OP-1250, which has completed preclinical studies, and OP-3136. The company aims to improve outcomes for women living with cancer.